Outputs (76)

Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. (2024)
Journal Article
Wolfe, A. R., Cui, T., Baie, S., Corrales-Guerrero, S., Webb, A., Castro-Aceituno, V., …Lisanti, M. (2024). Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Science Advances, 10(9), eadj3551. https://doi.org/10.1126/sciadv.adj3551

Pancreatic ductal adenocarcinoma (PDAC) is characterized by its nutrient-scavenging ability, crucial for tumor progression. Here, we investigated the roles of caveolae-mediated endocytosis (CME) in PDAC progression. Analysis of patient data across di... Read More about Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions..

SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production (2022)
Journal Article
Mauro Lizcano, M., Sotgia, F., & Lisanti, M. (2022). SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production. Aging, 14(24), 9877-9889. https://doi.org/10.18632/aging.204452

Cancer stem cells (CSCs) are responsible for cancer recurrence, treatment failure and metastatic dissemination. As such, the elimination of CSCs represents one of the most important approaches for the future of cancer treatment. Among other propertie... Read More about SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production.

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation (2022)
Journal Article
Bonuccelli, G., Sotgia, F., & Lisanti, M. (2022). Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation. Aging, 14(23), 9466-9483. https://doi.org/10.18632/aging.204412

Here, we report the identification of key compounds that effectively inhibit the anchorage-independent growth and propagation of cancer stem cells (CSCs), as determined via screening using MCF7 cells, a human breast adenocarcinoma cell line. More spe... Read More about Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation.

New insights into cholesterol-mediated ERRα activation in breast cancer progression and pro-tumoral microenvironment orchestration. (2022)
Journal Article
Brindisi, M., Frattaruolo, L., Fiorillo, M., Dolce, V., Sotgia, F., Lisanti, M., & Cappello, A. (2022). New insights into cholesterol-mediated ERRα activation in breast cancer progression and pro-tumoral microenvironment orchestration. FEBS Journal, https://doi.org/10.1111/febs.16651

Breast cancer remains the greatest cause of cancer-related death in women worldwide. Its aggressiveness and progression derive from intricate processes that occur simultaneously both within the tumour itself and in the neighbouring cells that make up... Read More about New insights into cholesterol-mediated ERRα activation in breast cancer progression and pro-tumoral microenvironment orchestration..

High ATP production fuels cancer drug resistance and metastasis : implications for mitochondrial ATP depletion therapy (2021)
Journal Article
Fiorillo, M., Ozsvari, B., Sotgia, F., & Lisanti, M. (2021). High ATP production fuels cancer drug resistance and metastasis : implications for mitochondrial ATP depletion therapy. Frontiers in Oncology, 11, 740720. https://doi.org/10.3389/fonc.2021.740720

Recently, we presented evidence that high mitochondrial ATP production is a new therapeutic target for cancer treatment. Using ATP as a biomarker, we isolated the “metabolically fittest” cancer cells from the total cell population. Importantly, ATP-h... Read More about High ATP production fuels cancer drug resistance and metastasis : implications for mitochondrial ATP depletion therapy.

SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates migration in the MDA-MB-231 cell line (2021)
Journal Article
Di Pisa, F., Pesenti, E., Bono, M., Mazzarello, A., Bernardi, C., Lisanti, M., …Ghiotto, F. (2021). SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates migration in the MDA-MB-231 cell line. BMC Molecular and Cell Biology, 22(1), 41. https://doi.org/10.1186/s12860-021-00379-1

Background: The human SH3 domain Binding Glutamic acid Rich Like 3 (SH3BGRL3) gene is highly conserved in phylogeny and widely expressed in human tissues. However, its function is largely undetermined. The protein was found to be overexpressed in sev... Read More about SH3BGRL3 binds to myosin 1c in a calcium dependent manner and modulates migration in the MDA-MB-231 cell line.

MitoTracker Deep Red (MTDR) is a metabolic inhibitor for targeting mitochondria and eradicating cancer stem cells (CSCs), with anti-tumor and anti-metastatic activity in vivo (2021)
Journal Article
Sargiacomo, C., Stonehouse, S., Moftakhar, Z., Sotgia, F., & Lisanti, M. (2021). MitoTracker Deep Red (MTDR) is a metabolic inhibitor for targeting mitochondria and eradicating cancer stem cells (CSCs), with anti-tumor and anti-metastatic activity in vivo. Frontiers in Oncology, 11, 678343. https://doi.org/10.3389/fonc.2021.678343

MitoTracker Deep Red (MTDR) is a relatively non-toxic, carbocyanine-based, far-red, fluorescent probe that is routinely used to chemically mark and visualize mitochondria in living cells. Previously, we used MTDR at low nano-molar concentrations to... Read More about MitoTracker Deep Red (MTDR) is a metabolic inhibitor for targeting mitochondria and eradicating cancer stem cells (CSCs), with anti-tumor and anti-metastatic activity in vivo.

Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase (2021)
Journal Article
Fiorillo, M., Scatena, C., Naccarato, A., Sotgia, F., & Lisanti, M. (2021). Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell Death and Differentiation, 28(9), 2797-2817. https://doi.org/10.1038/s41418-021-00788-x

Here, we provide evidence that high ATP production by the mitochondrial ATP-synthase is a new therapeutic target for anticancer therapy, especially for preventing tumor progression. More specifically, we isolated a subpopulation of ATP-high cancer ce... Read More about Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase.

Anticancer Innovative Therapy Congress : highlights from the 10th anniversary edition (2021)
Journal Article
De Santis, F., Fucà, G., Schadendorf, D., Mantovani, A., Magnani, L., Lisanti, M., …Di Nicola, M. (2021). Anticancer Innovative Therapy Congress : highlights from the 10th anniversary edition. Cytokine and Growth Factor Reviews, 59, 1-8. https://doi.org/10.1016/j.cytogfr.2021.02.001

During the Tenth Edition of the Annual Congress on “Anticancer Innovative Therapy” [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the ro... Read More about Anticancer Innovative Therapy Congress : highlights from the 10th anniversary edition.

New insights in the expression of stromal caveolin 1 in breast cancer spread to axillary lymph nodes (2021)
Journal Article
Scatena, C., Fanelli, G., Fanelli, G., Menicagli, M., Aretini, P., Ortenzi, V., …Naccarato, A. (2021). New insights in the expression of stromal caveolin 1 in breast cancer spread to axillary lymph nodes. Scientific reports, 11(1), 2755. https://doi.org/10.1038/s41598-021-82405-y

Recent evidence suggests that a loss of expression of caveolin in the stromal compartment (sCav-1) of human invasive breast carcinoma (IBC) may be a predictor of disease recurrence, metastasis and poor outcome. At present, there is little knowledge r... Read More about New insights in the expression of stromal caveolin 1 in breast cancer spread to axillary lymph nodes.